Dapagliflozin, Linagliptin

Dapagliflozin and Linagliptin is a combination medication that combines the actions of two different substances to treat type 2 diabetes. Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor, and Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor.
Dapagliflozin works by blocking the reabsorption of glucose in the kidneys, which helps to eliminate excess glucose from the body through urine. Linagliptin, on the other hand, inhibits the breakdown of incretin hormones in the body, such as GLP-1, which stimulates the release of insulin from the pancreas. By lowering blood sugar levels, this combination medication can effectively manage type 2 diabetes and help improve glycemic control.
Dapagliflozin and Linagliptin is typically prescribed when other treatments, such as lifestyle modifications or single-agent therapies, have failed to achieve satisfactory blood sugar control. It can be used in patients with type 2 diabetes, regardless of age, who need to lower their blood sugar levels without the need for insulin.